Status:
NOT_YET_RECRUITING
Topical Thymoquinone in Psoriasis Vulgaris
Lead Sponsor:
Assiut University
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
A previous trial found that N. sativa oil was more effective as an antipsoriatic agent, particularly when taken as both a cream and a pill. This confirmed that N. sativa possesses antipsoriatic proper...
Detailed Description
Psoriasis is a systemic chronic relapsing immune-mediated disease which often requires a long-term therapy. Psoriasis occurs in around 2-3% of the total global population. In Egypt, the prevalence of ...
Eligibility Criteria
Inclusion
- Patients with clinical diagnosis of mild psoriasis vulgaris
- Age: between 18 and 60 years' old
- Patients who stopped any systemic therapy or phototherapy for at least 3 months and topical therapy for at least 4 weeks prior to enrollment
Exclusion
- Psoriasis vulgaris involving \> 10% of the body surface area, pustular or erythrodermic psoriasis.
- Pregnant or lactating females.
- Patients with any current dermatological disease.
- Patients with any current systemic disease.
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06508372
Start Date
August 1 2024
End Date
January 1 2025
Last Update
July 19 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.